CRST participated in the 15th annual Clinical Trials on Alzheimer's Disease (CTAD) conference in San Francisco on 29.10.– 2.11. 2022 CTAD is a meeting entirely focused on therapeutic trials in Alzheimer’s disease (AD). It aims to accelerate the development of new…


Avilex Pharma - Customer's story The first-in-human Phase 1 clinical trial of Avilex Pharma’s lead candidate AVLX-144 was conducted successfully in collaboration with Clinical Research Services Turku (CRST) in Finland. During the course of the Phase I study, AVLX-144 was…

CRST collaborates with the local Alzheimer associations CRST has been collaborating with the local associations of The Alzheimer Society of Finland for several years. The Alzheimer Society of Finland is a non-profit organisation providing help and assistance for people with Alzheimer's disease…

CRST is arranging a crowdfunding share emission together with Invesdor Nordics From its inception as a company, CRST has been aiming to grow profitably. After seven years of profitable growth and after reaching a turnover of €3,1M (in 2020), planning…

CRST's CSO Mika Scheinin was nominated as the Clinical Investigator of the Year 2022 CRST's CSO Mika Scheinin was nominated as the Investigator of the Year 2022 at the Clinical Trials Forum of the Pharmaceutical Information Centre/ Pharma Industry Finland.Congratulations…
Recent Posts
- LINK Medical AS acquires Finnish clinical research service company CRST Oy.
- CRST and Kancera AB signed a contract for a First-in-human trial with KAND145
- CRST has appointed Petri Vainio as the CRST’s new Chief Scientific Officer
- CRST’s scientific team contributed in a study evaluating an ASO in mild Alzheimer’s disease
- Lihavuuden lääkehoidossa kohti mullistusta